JP2023543261A5 - - Google Patents

Info

Publication number
JP2023543261A5
JP2023543261A5 JP2023519178A JP2023519178A JP2023543261A5 JP 2023543261 A5 JP2023543261 A5 JP 2023543261A5 JP 2023519178 A JP2023519178 A JP 2023519178A JP 2023519178 A JP2023519178 A JP 2023519178A JP 2023543261 A5 JP2023543261 A5 JP 2023543261A5
Authority
JP
Japan
Application number
JP2023519178A
Other languages
Japanese (ja)
Other versions
JPWO2022067347A5 (https=
JP2023543261A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/071606 external-priority patent/WO2022067347A1/en
Publication of JP2023543261A publication Critical patent/JP2023543261A/ja
Publication of JPWO2022067347A5 publication Critical patent/JPWO2022067347A5/ja
Publication of JP2023543261A5 publication Critical patent/JP2023543261A5/ja
Withdrawn legal-status Critical Current

Links

JP2023519178A 2020-09-28 2021-09-27 ツカチニブを抗her2抗体と組み合わせて用いてher2変化により駆動される固形腫瘍を処置する方法 Withdrawn JP2023543261A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063084481P 2020-09-28 2020-09-28
US63/084,481 2020-09-28
US202063113245P 2020-11-13 2020-11-13
US63/113,245 2020-11-13
US202163222335P 2021-07-15 2021-07-15
US63/222,335 2021-07-15
PCT/US2021/071606 WO2022067347A1 (en) 2020-09-28 2021-09-27 Methods of treating solid tumors driven by her2 alterations with tucatinib in combination with an anti-her2 antibody

Publications (3)

Publication Number Publication Date
JP2023543261A JP2023543261A (ja) 2023-10-13
JPWO2022067347A5 JPWO2022067347A5 (https=) 2024-10-07
JP2023543261A5 true JP2023543261A5 (https=) 2024-10-07

Family

ID=78464001

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023519178A Withdrawn JP2023543261A (ja) 2020-09-28 2021-09-27 ツカチニブを抗her2抗体と組み合わせて用いてher2変化により駆動される固形腫瘍を処置する方法

Country Status (10)

Country Link
US (1) US20230372342A1 (https=)
EP (1) EP4217400A1 (https=)
JP (1) JP2023543261A (https=)
KR (1) KR20230078705A (https=)
CN (1) CN116437924A (https=)
AU (1) AU2021349384A1 (https=)
CA (1) CA3197165A1 (https=)
IL (1) IL301405A (https=)
MX (1) MX2023003406A (https=)
WO (1) WO2022067347A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023230429A1 (en) * 2022-05-22 2023-11-30 Seagen Inc. Methods of treating colorectal cancer with tucatinib in combination with an anti-her2 antibody
TW202502352A (zh) 2023-03-10 2025-01-16 美商思進公司 使用抗her2抗體-藥物結合物及her2激酶抑制劑治療癌症之方法
TW202541808A (zh) 2023-12-20 2025-11-01 德商百靈佳殷格翰國際股份有限公司 抗癌組合治療

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4683203A (en) 1984-04-14 1987-07-28 Redco N.V. Immobilized enzymes, processes for preparing same, and use thereof
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
IE61148B1 (en) 1988-03-10 1994-10-05 Ici Plc Method of detecting nucleotide sequences
US5055303A (en) 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
US5271961A (en) 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US5498531A (en) 1993-09-10 1996-03-12 President And Fellows Of Harvard College Intron-mediated recombinant techniques and reagents
US5413197A (en) 1994-03-14 1995-05-09 Baer; Larry G. Parking brake valve
EP3615695A1 (en) 2017-04-24 2020-03-04 Genentech, Inc. Erbb2/her2 mutations in the transmebrane or juxtamembrane domain
CA3060407A1 (en) * 2017-04-28 2018-11-01 Seattle Genetics, Inc. Treatment of her2 positive cancers
TW202042820A (zh) * 2019-01-28 2020-12-01 美商西雅圖遺傳學股份有限公司 以妥卡替尼(Tucatinib)治療乳癌之方法

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
JP2022523045A5 (https=)
JP2023543261A5 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR112023016292A2 (https=)
BR202021024548U2 (https=)
BR112023011610A2 (https=)
BR112023011539A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021016176A2 (https=)
BR102021015566A2 (https=)
BR102021015450A8 (https=)